EVAluation of the Non Inferiority of Interpretability of Cardiokin Compared to Holter

NCT ID: NCT03932227

Last Updated: 2020-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-08

Study Completion Date

2020-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to evaluate the electrocardiogram quality signal of the Cardioskin device and compare it with a Holter signal. For that, volunteers subjects will wear the Cardioskin and Holter, non-simultaneously, for about 24 hours.

This study is open, and will be carried out according to a cross plan. The trial will include approximately 36-40 subjects between 18 and 70 years old.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The wear of the first device will be randomized. Each subject will wear the two devices.

One group will start with a 24-hour environmental recording with Cardioskin and then will perform another recording of about 24 hours with the Holter. Conversely, group B will start with the Holter and then will continue with Cardioskin. It is a randomization software that will assign a group to each included participant.

Each participant will come three times at hospital : one for inclusion and equipment of the first device, another to be unequipped and equipped of the second device. They will come another time to bring back the material. The total time of participation is of two days and half.

The first aim is to evaluate if the signal interpretability is non-inferior to an Holter, for a recording of 24h (classic analysis of rhythm).

The second aim is to evaluate if the 24 hours signal interpretability is non-inferior to an Holter in the case of a repolarization analysis.

The third aim is to compare the comfort and usability between Cardioskin and Holter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Monocentric, cross study, randomized
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardioskin-Holter

Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.

Group Type OTHER

Cardioskin

Intervention Type DEVICE

Subjects will have a 24h recording with Cardioskin, next will be unequipped.

Holter

Intervention Type DEVICE

Subjects will have a 24h recording with Holter, next will be unequipped.

Holter-Cardioskin

Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.

Group Type OTHER

Cardioskin

Intervention Type DEVICE

Subjects will have a 24h recording with Cardioskin, next will be unequipped.

Holter

Intervention Type DEVICE

Subjects will have a 24h recording with Holter, next will be unequipped.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardioskin

Subjects will have a 24h recording with Cardioskin, next will be unequipped.

Intervention Type DEVICE

Holter

Subjects will have a 24h recording with Holter, next will be unequipped.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* people between 18 and 70 years old

Exclusion Criteria

* Minors
* Pregnant, parturient or breastfeeding women
* Refusal of consent
* Participant with known cardiac history
* Participant with cardiac arrhythmia observed during control ECG
* Participant who may be exposed to ionizing or electromagnetic radiation on days when devices (Cardioskin, Holter) will be worn
* Allergy to one of the components of the Cardioskin T-shirt, including:

Polyamide - Polyester - Elastane - Other synthetic materials - Silicone - Silver

* Allergy to one of the components of the electrodes used for the Holter (Kendall 530 or similar)
* Sensory disturbances that make the participant unresponsive to pain
* Motor or mental disorders that prevent the participant from expressing their pain -Behavioral problems that make the participant excessively Agitated or Aggressive
* Cardiorespiratory disorders that may be aggravated by mild compression of the chest
* Weight and / or size not suitable for the proposed Cardioskin T-shirt designs
* Open wound on the skin in the area covered by Cardioskin textile or by the electrodes of the Holter
* Irritation, and / or erythema in the area covered by the Cardioskin textile or by the electrodes of the Holter
* Pregnancy clinically detectable or known to a participant
* Participant with a high infectious risk
* Person wearing breast prostheses
* Simultaneous participation in another search
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioSerenity

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

European Hospital George Pompidou

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-A00922-55

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.